Combining tirzepatide with menopause hormone therapy enhances weight loss in postmenopausal women with overweight or obesity. A study found that those using both treatments lost an average of 17% of their total body weight, compared to 14% with tirzepatide alone. Furthermore, 45% of those receiving hormone therapy achieved at least 20% body weight loss. The study involved 120 participants over 18 months and highlights the effectiveness of concurrent menopause hormone therapy alongside tirzepatide for obesity treatment.
These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women.
Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications.
The results showed superior total body weight loss percentage for women using tirzepatide plus menopause hormone therapy (17%) compared to those using tirzepatide alone (14%).
A higher percentage of menopause hormone therapy users (45%) also achieved at least 20% total body weight loss, compared to tirzepatide alone.
Collection
[
|
...
]